Review: New biological insights in early clinical studies

Hematological Oncology

Volumn 25, Issue 2, 2007, Pages 53-57

  Maur, Michela ^a   Sessa, Cristiana ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Biologically active dose; Early clinical studies; Phase I studies; Surrogate biomarker endpoint; Surrogate tissues

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GROWTH FACTOR RECEPTOR INHIBITOR; IMATINIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; CYTOSTASIS; CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMAGING SYSTEM; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; HUMANS; MAXIMUM TOLERATED DOSE; NEOPLASMS; RESEARCH DESIGN;

EID: 34250856309     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.808     Document Type: Review

References (53)

1. Reichert JM. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov 2003; 2: 695-702.
2. Gilbert J. Rebuilding big PhRMA's business model. In vivo(November), 73-80.
3. Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov 2004; 3(9): 763-769.
4. Tufts CDSS quantifies savings from boosting new drug R&D efficiency. Tufts CSDD Impact Report; 2002; 1-4.
5. Kummar S, Gutierrez M, Doroshow JH, et al. Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 2006; 62(1): 15-26.
6. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MF, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999; 91: 1281-1287.
7. Stadler WM, Ratain MJ. Development of target-based antineoplastic agents. Invest New Drugs 2000; 18: 7-16.
8. Ratain MJ, Stadler WM. Clinical trial designs for cytostatic agents. J Clin Oncol 2001; 19: 3154-3155.
9. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001; 19: 265-272.
10. Parulekar WR, Eisenhauer EA. Novel endpoints and design of early clinical trials. Ann Oncol 2002; 13(Suppl 4): 139-143.
11. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 2004; 96(13): 990-997.
12. Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist 2002; 7: 401-409.
13. Morabito A, Di Maio M, De Maio E, et al. Methodology of clinical trials with new molecular-targeted agents: where do we stand? Ann Oncol 2006; 17: (Suppl 7)vii 128-vii 131.
14. ASCO special article: critical role of Phase I clinical trials in cancer treatment. J Clin Oncol 1997; 15(2): 853-859.
15. Ratain MJ, Mick R, Schilsky RL, et al. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 1993; 85: 1637-1643.
16. Arbuck SG. Workshop on Phase I design: Ninth NCI EORTC New Drug Development Symposium, Amsterdam, March 12, 1996.
17. Simon R, Freidlin B, Rubinstein L, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997; 89: 1138-1147.
18. De George JJ, Ahn CH, Andrews PA, et al. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol 1998; 41: 173-185.
19. Eisenhauer EA, O'Dwyer PJ, Christian M, et al. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000; 18: 684-692.
20. Hidalgo M, Messersmith W. Pharmacodynamic studies in drug development. Educational book Proc Am Soc Clin Oncol 2004; 160-163.
21. Newell DR. How to develop a successful cancer drug-molecules to medicines or targets to treatments? Eur J Cancer 2005; 41: 676-682.
22. Park JW, Kerbel RS, Kelloff GJ, et al. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res 2004; 10: 3885-3896.
23. Kelloff GJ, Bast RC Jr, Coffey DS, et al. Biomarkers, surrogate end-points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res 2004; 10: 3881-3884.
24. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer correlation of relapse and survival with amplification of HER-2/neu oncogene. Science (Wash DC) 1987; 235: 177-182.
25. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer. National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst (Bethesda) 2000; 92: 1991-1998.
26. Colomer R, Llombart A, Ramos M, et al. Serum HER-2-ECD and the efficacy of letrozole in ER+/PR+ metastatic breast cancer: preliminary results of a prospective study. Breast Cancer Res Treat 2001; 69: 242.
27. Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002; 20: 1467-1472.
28. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
29. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001; 344: 783-792.
30. Park JW, Stagg R, Lewis GD, et al. Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. In Genes, Oncogenes, and Hormones: Advanced in Cellular and Molecular Biology of Breast Cancer, Dickson RB, Lippman ME (eds). Kluwer: Boston, 1992; 193-211.
31. Druker BJ. Imatinib alone or in combination for chronic myeloid leukaemia. Semin Hematol 2003; 98: 2039-2042.
32. Sawyers CL. Chronic myeloid leukaemia. N Engl J Med 1999; 340: 1330-1340.
33. Faderl S, Talpaz M, Estrov Z, et al. Chronic myelogenous leukaemia: biology and therapy. Ann Intern Med 1999; 131: 207-219.
34. Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-1082.
35. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001; 344: 1031-1037.
36. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukaemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539.
37. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec)is an active agent for gastrointestinal tumors, but does not yield responses in other soft-tissue sarcmas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group Phase II study. Eur J Cancer 2003; 39: 2006-2011.
38. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In Clinical Measurements in Drug Evaluation, Nimmo WS, Ticker GT (eds). John Wiley and Sons, Inc: New York, 1995; 1-2.
39. Spiro TP, Gerson SL, Liu L, et al. O6-Benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue alkyltransferase-directed DNA repair. Cancer Res 1999; 59: 2402-2410.
40. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005; 23: 5323-5333.
41. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005; 11: 7967-7985.
42. Lee L, Sharma S, Morgan B, et al. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PT787/ZK222584(PTK/ZK): translation of biological activity in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol 2005; 57: 1-11.
43. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955-3964.
44. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005; 23: 5464-5473.
45. Von Hoff DD, Turner J. Response rates, duration of response and dose response effects in phase I trials of antineoplastics. Invest New Drugs 1991; 9: 115-122.
46. Collins JM, Zaharko DS, Dedrick RL, et al. Potential roles for preclinical pharmacology in phase I trials. Cancer Treat Rep 1986; 70: 73-80.
47. Collins JM, Grieshaber CK, Chabner BA. Pharmacologically guided phase I trials based upon preclinical development. J Natl Cancer Inst 1990; 82: 1321-1326.
48. Babb J, Rogatko A, Zacks S:. Cancer phase I clinical trials: efficient dose escalations with overdose control. Stat Med 1998; 17: 1103-1120.
49. Rogatko A, Babb J.Escalation With Overdose Control (EWOC). http://www.fccc.edu/users/rogatko
50. Rogatko A, Babb JS, Tighiouart M, et al. New paradigm in dose-finding trials: patient-sepcific dosing and beyond phase I. Clin Cancer Res 2005; 11(15): August 1. 5342-5346.
51. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46: 33-48.
52. O'Quigley J. Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer. Biometrics 1992; 48: 853-862.
53. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995; 14: 1149-1161.